New study aims to find which MS drug better fights fatigue
NCT ID NCT06843382
First seen Nov 21, 2025 · Last updated Jun 16, 2026 · Updated 27 times
Summary
This study will follow 100 adults with multiple sclerosis who are starting either teriflunomide or dimethyl fumarate as part of their routine care. Over 12 months, researchers will measure how well participants can walk and think during sustained activities, along with their reported fatigue and quality of life. The goal is to see if one drug helps more with physical and mental tiredness, helping patients and doctors make better treatment choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Erciyes University
Kayseri, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.